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Summary 
 
Background: The A subunit of factor XIII (FXIII-A) functions as an intracellular 
transglutaminase (TG) in the megakaryocyte/platelet lineage where, likely, it 
participates in the cytoskeletal remodeling associated with cell activation. However, so 
far, the precise role of cellular FXIII (cFXIII) and the functional consequences of its 
absence in FXIII-A-deficient patients are unknown. Objectives and methods: In this 
work, we have used platelets from four patients with congenital deficiency of FXIII-A 
to study the role of cFXIII in platelet functions. Results: We report that FXIII-A 
represents the only detectable source of TG activity in platelets and that the binding of 
fibrinogen in response to TRAP stimulation was significantly reduced in platelets from 
the patients. In agreement, in control platelets, monodansyl-cadaverine (MDC), a 
competitive amino-donor for transglutaminases, inhibited in a dose-dependent manner 
fibrinogen binding induced by TRAP. Moreover, upon adhesion to fibrinogen, normal 
platelets incubated with MDC as well as FXIII-A-deficient platelets showed a distinct 
extension pattern with reduced lamellipodia and increased filopodia formation, 
suggesting a delay in spreading. Conclusions: These findings provide evidence 
supporting that cFXIII-dependent TG activity may be directly involved in the regulation 
of platelet functions. 
 
Key words: FXIII-A, platelet activation, transglutaminase activity 
Page 3 of 25Journal of Thrombosis and Haemostasis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
3 
Introduction 
 
Blood coagulation FXIII is a plasma transglutaminase (TG) that circulates as a 
heterotetramer composed of two catalytic A and two noncatalytic B subunits (A2B2) [1]. 
Much of plasma FXIII (pFXIII) is associated with fibrinogen, and it is activated by Ca2+ 
and thrombin in the final stage of the coagulation cascade, stabilizing the clot by cross-
linking γ and α chains of fibrin and by attaching plasmin inhibitor to the fibrin α-chain 
[2,3]. The intracellular form of FXIII (cFXIII) is a dimer of A subunits that can be 
activated by low Ca2+ concentrations in the absence of thrombin [4,5] and is present in a 
variety of cells including platelets, megakaryocytes, and monocytes/macrophages. 
Platelets contain amounts of FXIII-A 150 fold more per volume than plasma, while 
FXIII-A concentration in monocytes is at least one magnitude less than in platelets [6]. 
FXIII is a member of the TG family, composed of Ca2+-regulated cross-linking 
enzymes structurally similar to the papain-like cysteine proteases. Mammalian TGs can 
be distinguished on the basis of their tissue distribution, localization, and substrate 
specificity [7,8]. TG2 or tissue TG, the first member to be discovered, has unique 
characteristics such as ubiquitous expression, widespread localization and capacity to 
bind to guanine nucleotides. Evidence on the presence of TG2 in platelets comes mainly 
from a study that attributed to cFXIII only the thrombin-dependent TG activity [9]. 
Later, it was shown that the intracellular activation of FXIII does not require proteolytic 
cleavage, and that increase in cytosolic Ca2+ concentration induced by platelet activation 
is sufficient to trigger the active configuration [4,5,10]. Therefore, whether TG2 is 
significantly expressed and is contributing as a source of platelet TG activity is so far 
unclear. Furthermore, the functional significance of the high expression of cFXIII in 
platelets remains also poorly understood. 
No inherited disease has been identified associated to TG2 defect. However, a 
variety of mutations have been described in the FXIII subunit genes associated with 
bleeding tendency and pFXIII deficiency [11] (http://www.hgmd.cf.ac.uk/ac/index.php). 
The incidence of the disease, in the range of 1 in 2-3 million, is increasing as more 
laboratory support becomes available around the word. As a consequence of the absence 
of cross-linked fibrin, FXIII deficiency results in delayed bleeding after trauma and 
impaired wound healing, while primary hemostasis is apparently normal [12]. Umbilical 
bleeding in the first days after birth, repeated intracranial hemorrhages and recurrent 
early miscarriages are hallmarks of the disease. In patients carrying splice mutations, 
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small amounts of normally processed mRNA can produce FXIII to support partial 
dimerization of fibrin, thus reducing the clinical consequences [13]. Although 
heterozygous carriers are normally asymptomatic, some cases of bleeding have been 
reported [14]. 
In this report we have characterized the molecular defect in three cases of bleeding 
diathesis caused by FXIII-A deficiency. We used platelets from the patients as well as a 
competitive amino-donor for transglutaminases, monodansyl-cadaverine (MDC), to 
determine the source of platelet TG activity and to study the role of cFXIII in platelet 
function. 
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Patients, materials and methods 
 
Patients 
Patient 1 is a 34-year old female from Morocco with a history of frequent 
mucocutaneous bleeding and spontaneous miscarriages. Her parents are relatives. One 
of her sisters died due to hemorrhage and other has severe bleeding. Spanish patients 2 
and 3 are sisters with a lifelong bleeding tendency and abnormal wound healing. Their 
parents did not recognize consanguinity. Patient 4 is a Spanish 5-year old girl who has 
suffered two severe intracranial hemorrhages. Routine coagulation and platelet function 
tests were normal in all patients. Deficiency of pFXIII activity was determined by using 
the chromogenic Pefakit FXIII assay from Pentapharm (Basel, Switzerland). This study 
was approved by the hospital ethics Committee, and written informed consent for the 
use of blood sampling was obtained from the patients in accordance with the 
Declaration of Helsinki. 
 
Mutation identification 
Total platelet RNA was obtained using the guanidinium isothiocyanate procedure. 
Screening for mutations was performed by direct sequencing of PCR-amplified 
overlapping fragments of reversed transcribed FXIII-A mRNA. 
Genomic DNA was extracted from peripheral blood cells and the sequence of PCR 
products containing exons and flanking regions of introns of the F13A1 gene were 
analyzed following standard procedures. 
 
PCR-based relative quantification of FXIII-A and TG2 mRNA 
To compare the relative expression of FXIII-A and TG2 in platelets and human 
umbilical vein endothelial cells (HUVECS), a series of 30 µL-reverse transcription 
reactions were performed using a common antisense oligonucleotide, 5’-
AGGATGCCATCTTCAAACTG-3’, targeting sequences shared by both mRNAs. After 
cDNA synthesis, 5 µL-aliquots were used as template in 25, 30, 35 and 40-cycle PCR 
reactions, using specific sense oligonucleotides, 5’-GTCTGTGCGGCTGTCCATC-3’ 
and 5’-GCAAGACTGCACCTCG-3’, to amplify 285-bp cDNA fragments of FXIII-A 
and TG2, respectively. Amplification of a 163-bp fragment of β-actin cDNA was 
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carried out in parallel to verify that similar amounts of total RNA were used. The 
amplification products were resolved on agarose gels for densitometry analysis. 
 
Western analysis of platelet lysates 
Platelet proteins were solubilized in lysis buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 
1% Triton X-100, 0.05% Tween 20) supplemented with 1 mM phenylmethyl sulfonyl 
fluoride (PMS) and 5 µL/100 µL protease inhibitor cocktail (SIGMA). After 20 min on 
ice, lysates were cleared by centrifugation, quantified and resolved on SDS-10% PAGE 
under reduced conditions, transferred to PVDF membranes and incubated with a 
polyclonal antibody against FXIII-A (USBiological, Swanmpscott, MA, USA). The 
specific bound antibody was detected with a peroxidase-conjugated goat anti-rabbit IgG 
(BioRad) and visualized using the ECL chemiluminescent system. 
 
Binding of fibrinogen to activated platelets 
Purified human fibrinogen (Calbiochem) was labeled with FITC as previously 
described [15]. 
Washed platelets were resuspended in HEPES buffer, pH 7.4 (10 mM HEPES, 136 
mM NaCl, 2.7 mM KCl, 1 mM CaCl, 1 mM MgCl, 0.1% glucose) at a final 
concentration of approximately 5x107/mL. After 30 min of incubation at 37ºC with 
different concentrations of monodansyl-cadaverine (MDC), 100 µL aliquots were 
treated for 5 min at room temperature with 50 µM ADP plus 1 mM epinephrine, 25 µM 
TRAP-6, or 20 nM PMA. Then, FITC-Fg was added at 50 µg/mL and, after 20 min, 
platelets were washed and analyzed in a Coulter flow cytometer model EPICS XL. 
 
Platelet adhesion, spreading and immunofluorescence analysis 
Washed platelets were resuspended at approximately 4x108/mL in HEPES buffer and 
left at room temperature for 1 hour. For adhesion assays, 100 µL-aliquots were added to 
96 well plates coated with 3 µg/mL of purified human fibrinogen and incubated at 37ºC 
for 15 min. After washing twice, the number of adhering platelets was quantified in a 
colorimetric assay by measuring alkaline phosphatase activity [16]. 
For spreading and immunofluorescence assays, 500 µL-aliquots of platelet 
suspension were plated on glass coverslips coated with 3 µg/mL fibrinogen in 24-well 
culture dishes. After 15 min, they were fixed for 20 min in PBS containing 4% 
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paraformaldehyde, and blocked and permeabilized with 0.5% Triton X-100 in PBS-
0.5% BSA for 20 min at room temperature. Then, platelets were incubated with anti-β3 
(H1AG11) monoclonal antibody, and/or with an anti-FXIIIA polyclonal antibody in 
PBS containing 0.1% Triton X-100 and 10% normal goat serum for 1 hour. After 
washing, platelets were incubated with Alexa Fluor 488-conjugated anti-mouse and/or 
Alexa Fluor 546-conjugated anti-rabbit antibodies. After washing, the preparations were 
mounted on FluorSave reagent (Calbiochem) and visualized with an x63 objective with 
a Zeiss Axioplan epifluorescence microscope (Göttingen, Germany) equipped with a 
cooled CCD camera (Leica DFC 350 FX). Platelets were counted and classified 
according its spreading pattern in three categories: (i) platelets with sustained calcium 
induced phenotype (SCIP), (ii) platelets forming filopodia, and (iii) spread platelets 
forming lamellipodia. 
 
Multidimensional microscopy 
Platelets were prepared as described for spreading experiments and plated in 
microslides for live-cell-imaging (IBIDI, München, Germany) previously coated with 3 
µg/mL fibrinogen. Adhesion and spreading processes were monitored during 30 min in 
a multidimensional Leica AF6000 LX microscope, equipped with a CCD Hamamatsu 
C9100-02 camera in a CO2 and temperature controlled incubator. 
 
Cross-linking activity of platelet FXIII-A 
We measured TG activity in lysates of washed platelets using biotinylated 
cadaverine. Briefly, washed platelets were resuspended in 10 mM Tris-HCl, pH 7,4, 
containing 0.1% Triton X-100, 140 mM NaCl, 0.4 mM PMSF and 1 mM DTT, and 
lysed on ice for 20 min followed by three freezing-thawing cycles. After clearing by 
centrifugation, protein concentration was determined using the BIO-RAD Bradford dye 
method, and 30 µg of protein were incubated with 400 µM biotinylated cadaverine with 
or without 5 mM EDTA or 5 mM CaCl2, in a final volume of 15 µl of lysis buffer 
containing 3 mM DTT. After 1 hour at 37ºC the reactions were stopped by adding 
loading buffer and, then, resolved in 10% SDS-PAGE under reducing conditions, and 
transferred to PVDF membranes. The membranes were blocked with 5% non-fat milk, 
incubated with 1:4500 dilution of peroxidase-conjugated avidin, and visualized using 
the ECL chemiluminescent system. 
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Results 
 
Transglutaminase (TG) activity in platelets from FXIII-deficient patients 
Diagnosis of FXIII deficiency was based on the clinical history of hemorrhagic 
tendency and the absence of plasma FXIII activity revealed by an enzymatic assay. To 
determine whether the disorder was caused by a defect in the FXIII-A subunit, TG 
activity was determined in platelets lysates using cadaverine as competitive substrate. 
We observed that control platelets contained detectable basal TG activity that was 
blocked by EDTA and stimulated in the presence of calcium (Fig. 1A). This activity 
was absent in the patients suggesting that the disease is due to FXIII-A subunit 
deficiency. 
 
Identification of mutations in the F13A1 gene 
cDNA sequence analysis identified the Gly562Arg mutation in patient 1 (Fig. 2). Its 
homozygous status was verified by analyzing the gDNA. Platelets were found to 
contain normal mRNA levels of mutant FXIII-A, but they showed absence of protein in 
western and fluorescence microscopy analysis (Figs 1 and 3). Sequencing analysis 
revealed the presence of two main transcripts in patients 2 and 3. In one, the first 7 
bases of exon 6 were deleted; the other carried additional deletion of exon 5 (Fig. 2B). 
Analysis of gDNA identified the same mutation, IVS5-1G>A (Fig. 2A), in two different 
alleles for FXIII-A, as assessed by detection of Pro564Leu and Gln651Glu 
polymorphisms in heterozygosis. The results suggest that the IVS5-1G>A mutation 
activated a cryptic splice acceptor site in the 5’ sequence of exon 6 that is also 
preferentially used during splicing of intron 4 (Fig. 2B). The 7 bp-deleted transcript was 
also detected in a previously reported patient carrying the IVS5-1G>A mutation and 
low FXIII-A-mRNA levels [17]. In patient 4, cDNA sequencing revealed heterozygosis 
of Val34Leu polymorphism and similar amounts of two transcripts, one of them 
carrying deletion of exon 14 and, as consequence, frame-shift and premature stop 
codon. Sequence of the normal size transcript identified the G1985A substitution in 
exon 14 that would change Arg661 to Gln. Analysis of gDNA revealed heterozygous 
status for G1985A and identified, in the last nucleotide of exon 14, a heterozygous G>A 
transition (G2045A) which disrupts the donor splice sequence of intron 14. This 
mutation was not present in the PCR product corresponding to the normal size 
transcript, indicating that it always induces skipping of exon 14. 
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Platelet TG activity relies on the presence of cFXIII 
TG activity in platelet from FXIII-/- mice was recently shown to be higher than in 
normal mice, suggesting a compensatory up-regulation of another TG in FXIII-A-
deficient platelets [18]. The absence of TG activity in platelets from the patients (Fig. 1) 
suggests that cFXIII is, practically, the only source of platelet TG activity and that the 
murine compensatory TG activation is not operating in human platelets. Consistent with 
these findings, TG2 mRNA expression was undetectable relative to FXIII-A-mRNA 
levels in control platelets. In contrast, TG2, but not FXIII-A, was easily amplified in 
endothelial cells (Fig. 3). mRNA-TG2 was also barely expressed in FXIII-A-deficient 
platelets, independently of whether platelets contain normal (Fig. 3) or decreased (not 
shown) mRNA levels. 
 
Role of cFXIII in platelet functions 
Since cFXIII represents the main platelet TG activity we considered the possibility 
that it could modulate platelet activation response. We first determined the effect of 
different stimulators on fibrinogen binding to control and FXIII-A-deficient platelets. 
Platelets from the patients and, at least, two control individuals were analyzed together 
in two or more independent assays and, then, the values were pooled together for 
comparative analysis. The broad dispersion of the values does not imply variability in 
the response to activators; it is due, at least in part, to inter-experimental variability in 
the basal activation state of platelets during manipulation, as reflected in fibrinogen 
binding values in non-stimulated platelets. As shown in Fig. 4A, significant differences 
were only found in platelets stimulated with the thrombin receptor agonist hexapeptide 
TRAP. Consistent with this observation, monodansyl-cadaverine (MDC), a competitive 
amino-donor for transglutaminases [19], blocked in a dose-dependent manner the effect 
of TRAP on fibrinogen binding of control platelets (Fig 4B). 
We next compared adhesion of control and FXIII-A-deficient platelets to 3 µg/mL 
fibrinogen-coated surfaces. As shown in Fig. 5A, an altered spreading phenotype 
characterized by higher percent of platelets emitting filopodial versus lamellipodial 
extensions was observed in platelets from the patients. Consistent with this, incubation 
with MDC induced a dose-dependent increase of the proportion of control platelets 
showing filopodial processes. The effect of MDC was similar in control platelets seeded 
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on surfaces coated with 50 µg/mL fibrinogen or 33 µg/mL type I collagen (results not 
shown), but it was not observed in FXIII-A-deficient platelets (Fig. 5B). 
Complementary video microscopy analysis suggests that the higher number of FXIII-
defective platelets emitting filopodia reflects a delay in the rate of spreading (Fig. 6). 
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Discussion 
 
In the present work we failed to detect TG activity in four patients with diagnosis of 
plasma FXIII deficiency, which indicated that the defect was located in the A subunit of 
FXIII. Absence of TG activity in FXIII-deficient monocytes was previously reported 
[20]. Further immunofluorescence microscopy and western analysis of platelets 
revealed the absence of FXIII-A antigen, indicating that the molecular lesions affect 
mRNA expression and/or protein stability. 
The Gly562Arg mutation identified in patient 1 had been previously described [21]. 
Although normally synthesized, FXIII-A carrying Gly562Arg was reported to rapidly 
disappear in transfected cells, suggesting an altered conformation leading to rapid 
degradation [21]. According to these data, platelets from patient 1 contained normal 
levels of mutant mRNA but absence of FXIII-A antigen. Patients 2 and 3 inherited two 
different alleles of the FXIIIA1 gene carrying the same mutation, IVS5-1G>A, 
identified also in a previously reported case [17], suggesting that this recurrent mutation 
has occurred more than once on a different genetic background. The mutation disrupts 
the AG splice acceptor site of intron 5 and activates a cryptic AG dinucleotide in the 5’ 
sequence of exon 6, leading to the practical absence of normally spliced transcripts and 
the generation of reduced levels of a frame-shifted transcript due to deletion of the 7 
first bases of exon 6. Moreover, the RT-PCR analysis detected similar levels of another 
mutant transcript carrying an additional deletion of the upstream exon 5. Mutations in 
splice-donor sequences result in skipping of the entire upstream neighboring exon, 
while alterations at a splice acceptor site cause aberrant splicing of the downstream 
exon [22]. As far as we know, this is the first report of an acceptor sequence mutation 
resulting in skipping of the upstream exon. Since the outcome of splice site mutations 
may reflect the order of intron removal [23,24], the abnormal outcome of the IVS5-
1G>A mutation, together with the absence of mutant transcripts carrying only exon-5 
deletion, suggests that utilization of the new acceptor site in exon 6 speeds removal of 
intron 5 with respect to intron 4. Although most of the mRNA is probably degraded due 
to premature termination of the frame-shifted transcript, the GGTCAG/ATGGCA 
sequence generated in the new 7-bp deleted RNA intermediate may be preferred as an 
alternative to the normally used atgcag/ATGATG at intron 4-exon 5 boundary, resulting 
in skipping of exon 5. Even though deletion of exon 5 restores the correct reading 
frame, the scarce amount of mRNA and/or the likely aberrant folding of the mutant 
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protein may unable its detection. In patient 4 we found compound heterozygosis for two 
non-previously described mutations in exon 14 that result in normal amounts of two 
different transcripts. Thus, the absence of immunodetectable FXIII-A in platelets is 
probably due to the synthesis of misfolded polypeptides that are either unstable or 
rapidly degradated. 
Our results showing the practical absence of TG activity in FXIII-A deficient 
platelets indicate that platelet TG activity depends, basically, on the presence of cFXIII. 
Supporting this, TG2 mRNA levels were markedly reduced compared to those of FXIII-
A. Moreover, our data may also reveal a new difference between mouse and human 
platelet. As established for the species differences in PAR isoforms used to mediate 
thrombin signaling [25], human and mouse platelets may show a distinct relative 
expression and/or regulation of the TG family members. 
The functional implications of the high expression level of FXIII-A in platelets 
remain poorly understood [8]. Our results suggest a role for cFXIII in regulating platelet 
functions. A significant reduction of soluble fibrinogen binding in response to TRAP 
was observed in FXIII-A-deficient platelets, suggesting a role of cFXIII in TRAP-
induced platelet activation. Supporting these data, the competitive amino-donor of 
transglutaminases MDC was shown to block fibrinogen binding to control platelets 
stimulated by TRAP. It should be noted that in these assays the effect of MDC might 
also be due to competitive inhibition of plasma FXIII contained in the commercial 
preparation of fibrinogen. 
Platelet activation by most agonists results in a rise of free Ca2+, due to both influx 
across plasma membrane and release from internal stores. On the other hand, TG 
activity has been reported to increase in cytoskeletal fractions of activated versus non-
activated platelets [26]. Therefore, calcium concentration in TRAP-stimulated platelets 
could reach levels required for FXIII-A subunit activation. However, the apparent 
normal platelet response mediated by PMA or ADP plus epinephrine suggests that other 
mechanism could operate in platelets activated by TRAP. Increasing evidences suggest 
that dimerization of G-coupled protein receptors (GPCRs) regulate many receptor-
specific functions [27]. TG activity of cFXIII has been shown to be required for AT1 
receptor dimerization, which correlated with enhanced monocyte adhesion to 
endothelial cells at the onset of atherosclerosis [28]. Whether this mechanism could be 
applied to other seven transmembrane domain receptors is unknown, but is unlikely that 
it would be specific to AT1. Thus, the possibility exists that basal and/or stimulated 
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cFXIII transglutaminase activity plays a role in maintaining a level of protease-activated 
receptor (PAR) dimerization that, in turn, modulated platelet response upon TRAP 
stimulation. 
Platelet FXIII has been proposed to negatively regulate αIIbβ3 integrin function in 
collagen-adherent platelets [29]. The authors suggested that activation of platelet FXIII 
is involved in a mechanism by which sustained increases in cytosolic calcium flux, 
promoted by platelet adhesion to collagen, induce a switch from a pro-adhesive to a 
procoagulant phenotype, named as sustained calcium-induced platelet (SCIP) 
morphology, characterized by marked contraction of lamellipodial membranes, 
microvesiculation and platelet fragmentation. In our experimental conditions we 
observed a dose-dependent inhibitory effect of MDC on SCIP morphology in control as 
well in FXIII-A-deficient platelets adhered to fibrinogen (results not shown), suggesting 
that protein activities other than cFXIII may be involved in this process. In contrast, our 
experiments revealed that normal platelet spreading on fibrinogen-coated surfaces 
requires platelet expression and activity of cFXIII, suggesting a role for cFXIII in up-
regulating αIIbβ3 adhesive functions. These findings are consistent with the reported 
interaction of cFXIII with specific cytoskeletal proteins upon activation of intact 
platelets [26], and suggest an important role of cFXIII in the cytoskeletal remodeling 
associated with the adhesive function and/or contractility of platelets. In line with this 
observation, impaired phagocytosis has been described in monocytes from FXIII-
deficient patients [30]. 
The severity of bleeding symptoms due to plasma FXIII deficiency has made 
difficult to determine whether patients with mutations in FXIII-A subunit have a 
distinctive phenotype due to the concurrent lack of platelet cFXIII. The impaired 
platelet response observed in FXIII-A-deficient patients in the present report suggests 
that platelet dysfunction may represent a precipitating factor of bleeding in high-risk 
situations. Additional work is required to determine the precise function of platelet 
cFXIII. Moreover, it would be also of interest to define whether the apparently different 
TG activity in human and mouse platelets may have some haemostatic impact. 
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Legends to the figures 
 
Fig. 1. Intracellular FXIII-A expression and transglutaminase activity in platelets. 
(A) Platelet lysates from controls and plasma FXIII-deficient patients were incubated 
with biotinylated cadaverine in the absence or presence of EDTA or calcium, labelled in 
the figured as B, E and C, respectively, resolved by SDS-PAGE and blotted with 
peroxidase-conjugated avidin, as described in “Material and methods”. C: Control; P: 
Patient. (B) Control and FXIII-deficient platelets were seeded on fibrinogen coated 
coverslips, fixed and labelled with anti-β3 and FXIII-A antibodies, and analyzed by 
epifluorescence microscopy. Bar: 20 µm. (C) Western analysis of platelet FXIII-A in 
control and FXIII-A deficient platelets. 
 
Fig. 2. Identification of mutations in the F13A1 gene. (A) Direct sequencing of 
cDNA or genomic DNA (gDNA) amplification products of FXIII-A, showing 
homozygous Gly562Arg and IVS-1G>A in patients 1 and 2, respectively, and 
heterozygous Arg661Gln and G2045A in patient 4. (B) Dotted lines in the diagrams 
indicate the alternative splicing pattern induced by IVS6-2G>A and G2045A mutations 
in patients 2 and 4, respectively. 
 
Fig. 3. Relative expression of FXIII-A and TG2 mRNA in control and FXIII-A 
deficient platelets. PCR-based relative quantification of FXIII-A and TG2 mRNA was 
carried out as described in “Materials and methods”. (A) The amplification products 
from control and patient-1 platelets and from HUVEC cells were resolved on agarose 
gels y visualized by ethidium bromide staining. The figure shows a representative 
determination. (B) The analysis was repeated three times using different amounts of 
template mRNA and amplification products in a linear range were quantified by 
densitometry. 
 
Fig. 4. Agonist-induced fibrinogen binding to control and FXIII-A-deficient 
platelets. (A) Flow cytometry analysis of agonist-induced FITC-Fg binding to platelets 
from 10 control individuals and 4 FXIII-A-deficient patients. Washed platelets were 
stimulated with agonists for 5 min and, then, incubated with FITC-Fg as described in 
“Materials and methods”. In parentheses, the number of independent determinations. 
(B) Dose-dependent effect of MDC on TRAP-induced fibrinogen binding. Control 
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platelets were incubated with MDC at 37ºC for 30 min and, then processed, as before. 
The fluorescence values were calculated as products of the percent of gated positive 
platelets and the value of the mean channel, and expressed as percent of TRAP effect in 
the absence of MDC. Results are means + SD of determinations in, at least, platelets 
from five individuals. 
 
Fig. 5. Effect of MDC on spreading of control and FXIII-A-deficient platelets. 
Washed platelets were seeded on glass coverslips coated with 3 µg/mL fibrinogen and, 
after 15 min, fixed and labelled with anti-β3 moAb, and visualized as described in 
“Materials and methods”. (A) Representative spreading pattern of control and FXIII-A-
deficient platelets. F: platelets forming filopodia; L: spread platelets forming 
lamellipodia. Bar: 20 µm. (B) Dose-dependent effect of MDC on the relative number of 
filopodia- and lamellipodia-forming platelets from four controls and four FXIII-A-
deficient patients. 
 
Fig. 6. Real-time imaging of spreading of control and FXIII-A-deficient platelets 
on fibrinogen. Platelets from control and patient-1 were plated on 3 µg/mL-coated 
chambers and the adhesion-spreading process was monitored during 30 min using a 
multidimensional microscope as described in “Materials and methods”. Observation of 
a significant number of platelets revealed a delay in the rate of spreading of FXIII-A-
deficient platelets. The figure shows the behaviour of representative control and FXIII-
deficient platelets. 
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